FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - ValueSet, Realm US

13,139 resources

Type: Text:

By Version

By Authority

  • none: 1,981
  • hl7: 11,158

 

Start Prev Rows 12000 - 12200 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
signal.core.r4R4ValueSet/questionnaire-ccars-type-of-dischargeQuestionnaire CCARS Type Of Dischargedraft1pahl7
ca.on.dhdr.r4.v4R4ValueSet/dispense-categoryDispense Categoryactivehl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.974Message Error Condition Codes (HL7)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7806Assisted Living Exposure Type (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7718Healthcare Exposure Type (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3401Facility / Visit Type (Syndromic Surveillance)active2019-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.8015Food Product Consumed (Brucellosis)active2022-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3260Count Group Type (Flu)active2009-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7940Healthcare Occupation (COVID-19)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7717Legionella Exposure Setting (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.984Dwelling Typeactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3081Fetal Neonatal Infection Type (FDD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3091Maternal Infection (FDD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3136PCR Performed Lab Location (VPD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3139Serology Performed Lab Location (Pertussis)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7330Performing Laboratory Type (VPD)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3159Reporting Lab Typeactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7493Performing Lab Type (Arbovirus)active2016-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3090Lettuce Type (FDD)active2018-01
hl7.fhir.us.davinci-vbprR4ValueSet/lobLine of Business Value Settrial-use1cqi2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7949Treatment Type (COVID-19)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7997Treatment Type (Anthrax)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3160Microscopic Exam Type (TB)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7196Non Treponemal Serologic Test (STD)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3093Non Pork Type (FDD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3095Outbreak Type (FDD)active2008-01
hl7.fhir.us.davinci-vbprR4ValueSet/vbp-payment-streamPayment Stream Value Settrial-use1cqi2025-07hl7
hl7.fhir.us.davinci-drug-formularyR4ValueSet/PlanContactTypeVSType of plan contacttrial-usephx2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3096Pork Type (FDD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3100Seafood Type (FDD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7692Rehab Type (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7939Residence Type (COVID-19)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.825Referral Disposition (HL7)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7748Epidemiological Risk Factors (TB)active2019-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7708Rupture Type (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7998Severe Weather Type (Leptospirosis)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7683Substance Abuse (RIBD)active2019-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7329Type of Testing at CDC (NND)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3143Tetanus Type (VPD)active2008-01
hl7.fhir.us.mdiR4ValueSet/vs-tracking-number-typeTracking Number Typetrial-use3pher2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7197Treponemal Serologic Test (STD)active2020-01
signal.core.r4R4ValueSet/questionnaire-ccars-type-of-updateQuestionnaire CCARS Type Of Updatedraft1pahl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7335Vaccine Administered (Pertussis)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7448Vaccine Type (NND)active2022-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7688Vaccine Type (RIBD)active2018-01
hl7.fhir.us.davinci-raR4ValueSet/cc-typeCondition Category Typetrial-use2cqi2025-07hl7
hl7.fhir.us.davinci-vbprR4ValueSet/vbp-performance-metricPerformance Metrictrial-use1cqi2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3254Employment Status (Flu)active2009-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3314Specimen Type (Malaria)active2017-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7977Brucella Exposure (Brucellosis)active2021-01
hl7.fhir.us.pacio-adiR4ValueSet/ADIDocumentationTypeVSDocumentation Typestrial-use2pe2025-08hl7
signal.core.r4R4ValueSet/signal-organization-typeSignal Organization Typedraft2023-07hl7
hl7.fhir.us.Davinci-drug-formularyR4ValueSet/usdf-PharmacyTypeVSPharmacy Type VSdraft2020-01hl7
hl7.fhir.us.vdorR4ValueSet/vdor-types-of-treatment-for-substance-use-disorder-vsVDOR Types of Treatment for Substance Use Disorderinformativepher2025-06hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3121Birth Attendees (VPD)active2008-01
hl7.fhir.us.mcodeR4ValueSet/mcode-benign-uncertain-neoplasm-brain-cns-disorder-vsBenign Neoplasm of Brain and CNS Disorder Value Setactive4cic2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3058Cancer Typeactive2008-01
hl7.fhir.us.mcodeR4ValueSet/mcode-carcinoma-in-situ-disorder-vsCarcinoma In-Situ Disorder Value Setactive4cic2025-02hl7
hl7.fhir.us.davinci-pasR4ValueSet/PASCommunicationRequestMediumPAS Communication Medium Value Settrial-use3fm2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3210Contact Type (Hepatitis B)active2009-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.11.20.9.69.5Advance Directives Content Typesactive2024-04hl7
hl7.fhir.us.mcodeR4ValueSet/mcode-cytologic-evidence-malignancy-vsCytologic Evidence of Malignancy Value Setactive4cic2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3211Material exposure typeactive2009-01
hl7.fhir.us.mcodeR4ValueSet/mcode-hypereosinophilic-syndrome-disorder-vsSpecific Diagnosis of Cancer Value Setactive4cic2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7732Infection Type (RIBD)active2018-01
hl7.fhir.us.davinci-drug-formularyR4ValueSet/InsuranceItemTypeVSInsurance item typetrial-usephx2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3133Live Birth Outcome (Rubella)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.1006Type of Long Term Care Facilityactive2019-01
hl7.fhir.us.mcodeR4ValueSet/mcode-melanoma-in-situ-disorder-vsMelanoma In-Situ Disorder Value Setactive4cic2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3135Non-Live Birth Outcome (VPD)active2008-01
hl7.fhir.us.mcodeR4ValueSet/mcode-primary-malignant-neoplasm-disorder-vsPrimary Malignant Neoplasm Disorder Value Setactive4cic2025-02hl7
hl7.fhir.us.mcodeR4ValueSet/mcode-primary-cancer-disorder-vsPrimary Cancer Disorder Value Setactive4cic2025-02hl7
hl7.fhir.us.mcodeR4ValueSet/mcode-cancer-staging-prognostic-factor-type-vsCancer Staging Prognostic Factors Typesactivecic2025-02hl7
hl7.fhir.us.mcodeR4ValueSet/mcode-secondary-cancer-disorder-vsSecondary Cancer Disorder Value Setactive4cic2025-02hl7
hl7.fhir.us.davinci-pasR4ValueSet/PASSupportingInfoTypePAS Supporting Info Type Value Settrial-use3fm2025-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.10.20.22.5.300Transmission Based Precaution Typesactive2024-06hl7
hl7.cda.us.eyecareR5ValueSet/AidToVisionCodesAid to Vision Codesdraft2024-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7941Job Setting (COVID-19)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7647Typhoid Paratyphoid Serotype (FDD)active2017-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3111Typhoid Signs Symptoms (FDD)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3590Pulse Oximetry Unitactive2010-01
fhir.virtually.healthcareR4ValueSet/UKCorrelationIdentifierUK Common Resource Identifiersdraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/UKNationalIdentifiersUK National Insurance Identifiersdraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/ProfessionalLicenseUK Professional Licensedraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/StaffNumberUK StaffNumberdraft2025-08hl7
hl7.fhir.us.davinci-pctR4ValueSet/USClaimDRGCodesUS Claim DRG Codestrial-usefm2025-08hl7
fhir.cdc.opioid-cds-r4R4ValueSet/condition-us-core-health-concern-categoryUS Core Health Concern Condition Categoryactive2023-05hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.973Cityactive2020-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1196.4469Cabotegravir Injectable Productsactive2024-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1196.4470Emtricitabine oral for HIV PrEPactive2024-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1196.4474HIV Laboratory Based Testsactive2024-05hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3322Underlying Conditions (IPD)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7681Underlying Condition (RIBD)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7947Risk Factor (COVID-19)active2020-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3112Underlying Conditionsactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3402Age Unit (Syndromic Surveillance)active2011-01
hl7.fhir.us.codex-radiation-therapyR4ValueSet/codexrt-image-guided-radiotherapy-energy-unit-vsImage Guided Radiotherapy Energy Unit Value Setdraftcgp2025-02hl7
hl7.fhir.us.codex-radiation-therapyR4ValueSet/codexrt-radiotherapy-energy-unit-vsRadiotherapy Energy Unit Value Setdraftcgp2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7667Eosinophil Unitsactive2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.891Height Unitactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7372Time Units (NCHS)active2015-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.879Weight Unitactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7906Test result units (ARLN)active2019-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.838Units of Measureactive2015-01
hl7.fhir.us.pq-cmc-fdaR5ValueSet/pqcmc-non-percentage-unitsNon-Percentage Unitstrial-use2brr2025-07hl7
hl7.fhir.us.pq-cmc-fdaR5ValueSet/pqcmc-percentage-unitsPercentage Unitstrial-use2brr2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.920Blood Pressure Unitactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.878Age unitactive2015-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.919Temperature Unitactive2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7819Unit of Measure (TB)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7451Type of Testing at CDC (VZ)active2015-12
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7452Age Unit (NND)active2015-12
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7453Body Region(s) of Rashactive2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7454Character of Lesionsactive2015-12
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7474Type of Complication (VZ)active2017-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7456Lab Test Type (Varicella)active2018-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.11.20.9.41Tobacco Useactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1032.90Gestational Diabetesactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.2.1921Beta Blocker Therapy Ingredientactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1493Beta Blocker Therapy Ingredientactive2017-05hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.822Referral Priority (HL7)active2008-01
fhir.cdc.opioid-cds-r4R4ValueSet/cocaine-urine-drug-screening-testsCocaine urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/fentanyl-type-urine-drug-screening-testsFentanyl-type urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/opiate-specific-urine-drug-screening-testsOpiate specific urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/phencyclidine-urine-drug-screening-testsPhencyclidine urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/synthetic-opioid-urine-drug-screening-testsSynthetic opioid urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/all-urine-drug-screening-testsAll urine drug screening testsactive2023-11hl7
fhir.cdc.opioid-cds-r4R4ValueSet/methadone-urine-drug-screening-testsMethadone urine drug screening testsactive2023-05hl7
fhir.cdc.opioid-cds-r4R4ValueSet/amphetamine-urine-drug-screening-testsAmphetamine-class drugs and metabolite urine testsactive2023-05hl7
hl7.fhir.us.vdorR4ValueSet/vdor-use-of-prescription-morphine-vsVDOR Use of Prescription Morphineinformativepher2025-06hl7
signal.core.r4R4ValueSet/contact-point-useContactPointUsedraft0fhir2019-10hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.2.11.7101VPD Reason for Studyactive2013-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.227Neoplasm of Brainactive2024-07hl7
hl7.fhir.us.carin-bbR4ValueSet/C4BBAdjudicationCategoryDiscriminatorC4BB Adjudication Category Discriminator Value Settrial-usefm2025-02hl7
hl7.fhir.us.davinci-pdexR4ValueSet/PDexAdjudicationCategoryDiscriminatorPDex Adjudication Category Discriminatorinformativefm2025-06hl7
hl7.fhir.us.carin-bbR4ValueSet/C4BBSupportingInfoTypeC4BB SupportingInfo Type Value Settrial-usefm2025-02hl7
hl7.fhir.us.davinci-pdexR4ValueSet/PDexSupportingInfoTypePDex SupportingInfo Typeinformativefm2025-06hl7
hl7.fhir.us.carin-bbR4ValueSet/C4BBTotalCategoryDiscriminatorC4BB Total Category Discriminator Value Settrial-usefm2025-02hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7367Exposure Time Frame (NND)active2015-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.11.20.9.44Mental and Functional Status Responseactive2024-06hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.5015Role (PHLIP)active2011-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.244Anthracycline Injectableactive2024-10hl7
hl7.fhir.us.coreR4ValueSet/us-core-clinical-result-observation-categoryUS Core Clinical Result Observation Categorytrial-use3cgp2023-04hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7378Death Reporting Name Type Code (NCHS)active2016-01
us.nlm.vsacR4ValueSet/2.16.840.1.113883.1.11.11610x_ActRelationshipDocumentactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.1.11.16926HL7 BasicConfidentialityKindactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1029.67Other Health Care Facilityactive2025-05hl7
us.cdc.phinvadsR4ValueSet/1.3.6.1.4.1.19376.1.7.3.1.1.15.2.2JCIH-EHDI Outpatient Encounteractive2010-01
hl7.fhir.us.pacio-pfeR4ValueSet/pfe-survey-category-vsPersonal Functioning and Engagement Survey Value Settrial-use3pc2025-07hl7
hl7.fhir.us.icsr-ae-reportingR4ValueSet/ICSRAESeriousnessICSR Top-Level Seriousnessdraft2023-08hl7
signal.core.r4R4ValueSet/data-absent-reasonDataAbsentReasonnormative5fhir2019-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1240.4Asked Declined Data Absent Reasonactive2023-06hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7442Death Reporting Event Type (NCHS)active2016-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3363Patient Class (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3365Relationship (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3366Financial Class (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3372Identifier Type (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3373Organizational Name Type (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3374Query Response Status (IIS)active2018-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3384Publicity Code (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3377Immunization Registry Status (HL7)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3378Immunization Registry Status (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3379Query Name (IIS)active2010-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.814Religion (HL7)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.816Route of Administration (HL7)active2008-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.812Production Class (HL7)active2008-01
signal.core.r4R4ValueSet/questionnaire-dacods-admission-route-of-administrationQuestionnaire DACODS Admission Route Of Administrationdraft1pahl7
signal.core.r4R4ValueSet/questionnaire-dacods-discharge-route-of-administrationQuestionnaire DACODS Discharge Route Of Administrationdraft1pahl7
fhir.virtually.healthcareR4ValueSet/VHConditionCodeVH Condition Codedraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/VHImmunisationCodeVH Immunisation Codedraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/VHMedicationCodeVH Medication Codedraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/VHObservationCodeVH Observation Codedraft2025-08hl7
fhir.virtually.healthcareR4ValueSet/VHObservationValueCodeVH Observation Value Codedraft2025-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.9ER Test for Orserduactive2023-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1248.185Spinal Surgeryactive2024-06hl7
fhir.giisR4ValueSet/VaccinationSiteVSVaccination body sitedraft2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7689Vaccination Information Source (RIBD)active2018-01
fhir.giisR4ValueSet/VaccinationReasonVSVaccination reasondraft2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.934Vaccines administered (CVX)active2022-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.3410Vaccine Not Given Reasons (NETSS)active2011-01
fhir.giisR4ValueSet/VaccineVSVaccine codesdraft2025-07hl7
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.7646Vaccine Received (FDD)active2017-01
us.cdc.phinvadsR4ValueSet/2.16.840.1.114222.4.11.1049Substance Administered (CRA)active2008-01
hl7.fhir.us.registry-protocolsR4ValueSet/NCDRErrorsVSNCDRErrorsVSactivecic2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.526.3.1489ACE Inhibitor or ARB or ARNI Ingredientactive2023-02hl7
hl7.fhir.us.davinci-pctR4ValueSet/PCTAdjudicationCategoryVSPCT GFE Item Adjudication Value Settrial-usefm2025-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.10.20.22.5.305Microbiology and Antimicrobial Susceptibility Testsactive2024-06hl7
hl7.fhir.us.directory-queryR4ValueSet/OrganizationAffiliationRoleVSOrganizationAffiliation Rolesactive2022-12hl7
hl7.fhir.us.davinci-pdex-plan-netR4ValueSet/OrganizationAffiliationRoleVSOrganizationAffiliation Rolestrial-usefm2025-02hl7
hl7.fhir.us.ndhR4ValueSet/OrganizationAffiliationRoleVSOrganizationAffiliation Rolestrial-usepa2025-07hl7
hl7.fhir.us.directory-attestationR4ValueSet/OrganizationAffiliationRoleVSOrganizationAffiliation Rolesactive2022-12hl7
hl7.fhir.us.qicoreR4ValueSet/qicore-present-on-admissionQICore Present On Admission Codestrial-use4cqi2021-05hl7
fhir.nigeriaImmunizationR4ValueSet/register-client-valuesetIMMZ.C Value Set for Registering Clientsactive2025-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.11.20.9.37TargetSite Qualifiersactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1099.29Allergy Clinical Statusactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.1.11.1Administrative Gender (HL7 V3)active2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.1.11.20.2Advance Directive Type Codeactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.88.12.3221.8.9Body Site Value Setactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.1.11.18877Coverage Role Type Value Setactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.11.20.9.26EntityPersonNamePartQualifieractive2024-06hl7